Gain Scores, ANCOVA, and the Model Behind the Number
How Analytic Choices Shape Treatment Effect Estimates
This note is coming soon. It is Part 3 of a three-part series on Compass Pathways’ COMP360 psilocybin program for treatment-resistant depression.